This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Johnson & Johnson Remains Too Big to Succeed

NEW YORK ( TheStreet) -- Few stock sectors are as reliable as drugs and health care, and astute investors know that companies such as Merck (MRK), Pfizer (PFE) and Abbott Laboratories (ABT) have delivered healthy returns over the years.

One stock that investors have become less enamored with, however, is Johnson & Johnson (JNJ - Get Report).

Johnson and Johnson

The company has made recent mistakes, including product recalls, and its stock performance has been uninspiring for the most part.

Johnson & Johnson's first quarter was not so healthy, even though its numbers beat analysts' estimates.

Revenue was $16.1 billion, down slightly from the same quarter a year before.

Earnings were $3.8 billion, or $1.37 a share, up 1.5% from a year before.

But the headline numbers obscured some disappointing details.

Revenue from the U.S. declined by 5.1%.

The only unit that showed growth was business pharmaceutical sales, while consumer sales and medical devices declined by 2.4% and 0.3%, respectively.

Also disappointing was that management offered full-year EPS guidance of a conservative $5.07 to $5.17.

This failed to dispel concerns about litigation costs related to Johnson & Johnson's DePuy medical device unit.

Johnson & Johnson seems to have taken a "we know best" attitude when it comes to Wall Street's wish that it break itself into smaller and -- it is hoped -- more valuable parts.

Management's insistence on keeping the company one large conglomerate could make it lose loyal investors.

In fact, this insistence is remarkable when rivals Pfizer and Abbott Laboratories have enjoyed positive results from opting to separate their businesses.

Although I'd like to give Johnson & Johnson the benefit of the doubt on this issue because it's been in business so long, the company has yet to prove that it can make a solid turnaround as long as it stays "too big to succeed." Bottom Line

As dominant as Johnson & Johnson has been over the past several decades, it has stumbled repeatedly over the past five years.

Although Johnson & Johnson's shares are slightly less expensive than Pfizer's (PFE), its growth doesn't support its having a higher price-to-earnings multiple than Novartis (NVS) or Covidien (COV).

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
JNJ $100.34 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%
GOOG $548.34 0.00%
TSLA $185.00 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs